Drug Trial Radar · NCT04073680
A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
60
Planned (sponsor's estimate)
Start
Sep 1, 2020
Primary completion
Jul 15, 2021
Study completion Dec 30, 2021
Sponsor
- Lead sponsor
- Petra PharmaIndustry
- Sponsor type
- Industry
- First posted
- Aug 29, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to test the hypothesis that combining serabelisib, a PI3K alpha isoform inhibitor, with an SGLT2 inhibitor, canagliflozin will improve efficacy in the treatment of patients with advanced solid tumors.
Conditions
- Breast Cancer
- Endometrial Cancer
- Lung Cancer
- Colo-rectal Cancer
- Head and Neck Cancer
Interventions
SerabelisibDrug
Subjects will be dosed with Serabelisib on 3 consecutive days a week in a 28 day cycle until tumor progression. in combination with Canagliflozin 300mg, both are oral medications
Canagliflozin 300mgDrug
All subjects will be dosed with 300 mg canagliflozin in combination with serabelisib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Adverse EventsTime frame: 30 days after last dose
- Rate of Laboratory AbnormalitiesTime frame: 30 days after last dose
- Dose confirmationTime frame: 6 months
- Tumor Assessments by RESISTTime frame: 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.